ANI Pharmaceuticals, Inc. $ANIP Stock Holdings Lifted by Public Sector Pension Investment Board

Public Sector Pension Investment Board boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 16.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,377 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,324 shares during the quarter. Public Sector Pension Investment Board’s holdings in ANI Pharmaceuticals were worth $6,172,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANIP. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC acquired a new position in ANI Pharmaceuticals in the 1st quarter worth about $2,706,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim boosted their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Barclays assumed coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective on the stock. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $103.43.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 4,322 shares of company stock valued at $354,816 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $77.81 on Thursday. The company has a fifty day moving average price of $80.95 and a two-hundred day moving average price of $86.30. ANI Pharmaceuticals, Inc. has a one year low of $54.10 and a one year high of $99.50. The stock has a market cap of $1.75 billion, a P/E ratio of 47.74 and a beta of 0.50. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.